IRIS
BASSET, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.756
AS - Asia 1.344
EU - Europa 1.055
SA - Sud America 199
AF - Africa 92
OC - Oceania 3
Totale 4.449
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.711
CN - Cina 480
SG - Singapore 333
IE - Irlanda 315
VN - Vietnam 186
HK - Hong Kong 161
BR - Brasile 152
RU - Federazione Russa 152
DE - Germania 133
IT - Italia 105
FI - Finlandia 103
ZA - Sudafrica 74
FR - Francia 66
IN - India 56
GB - Regno Unito 49
CA - Canada 28
JP - Giappone 26
SE - Svezia 25
BD - Bangladesh 19
PL - Polonia 18
ES - Italia 15
AT - Austria 13
NL - Olanda 13
CO - Colombia 12
IQ - Iraq 12
AR - Argentina 11
MX - Messico 11
TR - Turchia 10
LT - Lituania 9
PK - Pakistan 8
CL - Cile 7
ID - Indonesia 7
SA - Arabia Saudita 7
PH - Filippine 6
AL - Albania 5
CZ - Repubblica Ceca 5
BE - Belgio 4
BO - Bolivia 4
EC - Ecuador 4
EG - Egitto 4
GR - Grecia 4
TN - Tunisia 4
VE - Venezuela 4
AU - Australia 3
AZ - Azerbaigian 3
IR - Iran 3
JO - Giordania 3
LV - Lettonia 3
MA - Marocco 3
UA - Ucraina 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
BG - Bulgaria 2
HR - Croazia 2
IL - Israele 2
JM - Giamaica 2
KE - Kenya 2
KR - Corea 2
LB - Libano 2
LU - Lussemburgo 2
MN - Mongolia 2
MU - Mauritius 2
MY - Malesia 2
PE - Perù 2
PT - Portogallo 2
UY - Uruguay 2
UZ - Uzbekistan 2
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CH - Svizzera 1
DK - Danimarca 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
HN - Honduras 1
LK - Sri Lanka 1
MK - Macedonia 1
NG - Nigeria 1
PY - Paraguay 1
QA - Qatar 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SL - Sierra Leone 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TM - Turkmenistan 1
TT - Trinidad e Tobago 1
VC - Saint Vincent e Grenadine 1
Totale 4.449
Salva come PNG Salva come JPEG
Città #
Dublin 313
Chandler 208
Ashburn 198
Singapore 191
Dallas 187
San Jose 174
Hong Kong 155
Beijing 145
Helsinki 77
Los Angeles 73
Ho Chi Minh City 71
Johannesburg 70
Nanjing 55
Munich 49
Boardman 48
Lauterbourg 45
Hanoi 43
New York 43
Shanghai 36
Princeton 35
Lawrence 34
Medford 31
Wilmington 26
Pavia 25
Tokyo 24
Nanchang 21
Milan 20
Moscow 20
Council Bluffs 19
Jacksonville 19
Orem 19
São Paulo 19
Chennai 18
Redondo Beach 18
Buffalo 17
Changsha 16
Montreal 15
Shenyang 15
Warsaw 15
Chicago 14
Da Nang 14
Hebei 14
Piscataway 14
Turku 14
Nuremberg 13
Tianjin 13
Santa Clara 12
Denver 11
Frankfurt am Main 10
Haiphong 10
Jiaxing 10
Poplar 10
Stockholm 10
Falkenstein 9
Houston 9
London 9
San Francisco 9
Amsterdam 8
Ankara 8
Pune 8
Seattle 8
Vienna 8
Brooklyn 7
Hangzhou 7
Hải Dương 7
Manchester 7
Norwalk 7
Toronto 7
Atlanta 6
Rio de Janeiro 6
Tamm 6
The Dalles 6
Woodbridge 6
Catania 5
Fairfield 5
Hyderabad 5
Mexico City 5
Redwood City 5
Tirana 5
Baghdad 4
Bexley 4
Boston 4
Brasília 4
Brussels 4
Cagliari 4
City of London 4
Phoenix 4
Washington 4
Amman 3
Athens 3
Baku 3
Biên Hòa 3
Brno 3
Charleston 3
Charlotte 3
Go Vap 3
Guayaquil 3
Jeddah 3
Jinan 3
La Paz 3
Totale 3.026
Salva come PNG Salva come JPEG
Nome #
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 127
A patient with AL amyloidosis with negative free light chain results 123
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 123
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 120
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 119
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 119
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 118
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 115
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 110
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 106
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 105
Prognostication of survival and progression to dialysis in AA amyloidosis 105
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 102
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies 101
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 99
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 98
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 98
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 97
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 97
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 96
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 93
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 91
A case of monoclonal gammopathy of renal significance 91
Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome 89
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 89
Analysis of cyclin D1 mRNA expression levels in plasma cell dyscrasias: A systematic review of published literature 88
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 83
Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis 82
Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis 81
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 80
Development and Validation of Staging Systems for AA Amyloidosis 79
The lung in amyloidosis 78
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis 78
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis 77
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 76
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis 75
A biomarker-based approach in management of AL amyloidosis: from risk assessment to tailored-treatment strategy 74
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 73
A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis 68
A Strategy for the Selection of RT-qPCR Reference Genes Based on Publicly Available Transcriptomic Datasets 66
Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis 62
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis 61
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 60
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside 58
Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis 54
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 53
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival 53
Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study 51
Treatment of AL amyloidosis with bendamustine: A study of 122 patients 47
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients 47
Predictors of Early Death in Patients With Wild-Type Transthyretin Cardiac Amyloidosis 38
Renal amyloidoses 34
Feasibility of a Biomarker-Based Screening for Pre-Symptomatic AL Amyloidosis in Patients With Intermediate/High-Risk MGUS 31
null 30
null 29
Left ventriculo-arterial coupling in a contemporary cohort of patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis 25
Diffuse lung involvement as a rare presentation of systemic AL amyloidosis: a retrospective cohort study 23
null 6
Totale 4.551
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.833
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.833
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214 0 0 0 0 0 0 0 0 0 2 0 2
2021/2022154 2 0 1 0 5 3 0 12 9 14 17 91
2022/2023698 59 62 11 31 46 56 13 35 351 3 21 10
2023/2024362 44 78 17 26 30 68 12 20 2 15 21 29
2024/2025864 27 57 9 28 10 75 79 35 210 50 107 177
2025/20262.105 147 149 193 308 319 85 389 144 253 118 0 0
Totale 4.551